|
1
|
Enzinger PC and Mayer RJ: Esophageal
cancer. N Engl J Med. 349:2241–2252. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Lin Y, Totsuka Y, He Y, Kikuchi S, Qiao Y,
Ueda J, Wei W, Inoue M and Tanaka H: Epidemiology of esophageal
cancer in Japan and China. J Epidemiol. 23:233–242. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Zhang Y: Epidemiology of esophageal
cancer. World J Gastroenterol. 19:5598–5606. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Wu M, Zhao JK, Zhang ZF, Han RQ, Yang J,
Zhou JY, Wang XS, Zhang XF, Liu AM, van't Veer P, et al: Smoking
and alcohol drinking increased the risk of esophageal cancer among
Chinese men but not women in a high-risk population. Cancer Causes
Control. 22:649–657. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Siegel RL, Miller KD and Jemal A: Cancer
statistics, 2016. CA Cancer J Clin. 66:7–30. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
LeVea C: Pathogenesis of Esophageal Cancer
[M]/Minimally Invasive Foregut Surgery for Malignancy. Springer
International Publishing; pp. 1–9. 2015
|
|
7
|
Weaver BA and Cleveland DW: Decoding the
links between mitosis, cancer, and chemotherapy: The mitotic
checkpoint, adaptation, and cell death. Cancer Cell. 8:7–12. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Britigan EM, Wan J, Zasadil LM, Ryan SD
and Weaver BA: The ARF tumor suppressor prevents chromosomal
instability and ensures mitotic checkpoint fidelity through
regulation of Aurora B. Mol Biol Cell. 25:2761–2773. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Li F, Ambrosini G, Chu EY, Plescia J,
Tognin S, Marchisio PC and Altieri DC: Control of apoptosis and
mitotic spindle checkpoint by survivin. Nature. 396:580–584. 1998.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Gu Y, Li P, Peng F, Zhang M, Zhang Y,
Liang H, Zhao W, Qi L, Wang H, Wang C and Guo Z: Autophagy-related
prognostic signature for breast cancer. Mol Carcinog. 55:292–299.
2016. View
Article : Google Scholar : PubMed/NCBI
|
|
11
|
Wang R, Kang Y, Löhr CV, Fischer KA,
Bradford CS, Johnson G, Dashwood WM, Williams DE, Ho E and Dashwood
RH: Reciprocal regulation of BMF and BIRC5 (Survivin) linked to
Eomes overexpression in colorectal cancer. Cancer Lett.
381:341–348. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Lim T, Lee I, Kim J and Kang WK:
Synergistic effect of simvastatin plus radiation in gastric cancer
and colorectal cancer: Implications of BIRC5 and connective tissue
growth factor. Int J Radiat Oncol Biol Phys. 93:316–325. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Vaĭshlia NA, Zinov'eva MV, Sass AV,
Kopantsev EP, Vinogradova TV and Sverdlov ED: Increase of BIRC5
gene expression in non-small cell lung cancer and esophageal
squamous cell carcinoma does not correlate with expression of genes
SMAC/DIABLO and PML encoding its inhibitors. Mol Biol (Mosk).
42:652–661. 2007.(In Russian).
|
|
14
|
Rice TW and Blackstone EH: Esophageal
cancer staging: Past, present, and future. Thorac Surg Clin.
23:461–469. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Zhao P, Meng Q, Liu LZ, You YP, Liu N and
Jiang BH: Regulation of survivin by PI3K/Akt/p70S6K1 pathway.
Biochem Biophys Res Commun. 395:219–224. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Ambrosini G, Adida C and Altieri DC: A
novel anti-apoptosis gene, survivin, expressed in cancer and
lymphoma. Nat Med. 3:917–921. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Zu X, Ma J, Liu H, Liu F, Tan C, Yu L,
Wang J, Xie Z, Cao D and Jiang Y: Pro-oncogene Pokemon promotes
breast cancer progression by upregulating survivin expression.
Breast Cancer Res. 13:R262011. View
Article : Google Scholar : PubMed/NCBI
|
|
19
|
Hernandez JM, Farma JM, Coppola D, Hakam
A, Fulp WJ, Chen DT, Siegel EM, Yeatman TJ and Shibata D:
Expression of the antiapoptotic protein survivin in colon cancer.
Clin Colorectal Cancer. 10:188–193. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Lu D, Qian J, Yin X, Xiao Q, Wang C and
Zeng Y: Expression of PTEN and survivin in cervical cancer:
Promising biological markers for early diagnosis and prognostic
evaluation. Br J Biomed Sci. 69:143–146. 2012.PubMed/NCBI
|
|
21
|
Kato J, Kuwabara Y, Mitani M, Shinoda N,
Sato A, Toyama T, Mitsui A, Nishiwaki T, Moriyama S, Kudo J and
Fujii Y: Expression of survivin in esophageal cancer: Correlation
with the prognosis and response to chemotherapy. Int J Cancer.
95:92–95. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Kogo R, How C, Chaudary N, Bruce J, Shi W,
Hill RP, Zahedi P, Yip KW and Liu FF: The microRNA-218~Survivin
axis regulates migration, invasion, and lymph node metastasis in
cervical cancer. Oncotarget. 6:1090–1100. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Carmeliet P and Jain RK: Angiogenesis in
cancer and other diseases. Nature. 407:249–257. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Shojaei F: Anti-angiogenesis therapy in
cancer: Current challenges and future perspectives. Cancer Lett.
320:130–137. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Zhu D, Hunter SB, Vertino PM and Van Meir
EG: Overexpression of MBD2 in glioblastoma maintains epigenetic
silencing and inhibits the antiangiogenic function of the tumor
suppressor gene BAI1. Cancer Res. 71:5859–5870. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Wang P, Zhen H, Zhang J, Zhang W, Zhang R,
Cheng X, Guo G, Mao X, Wang J and Zhang X: Survivin promotes glioma
angiogenesis through vascular endothelial growth factor and basic
fibroblast growth factor in vitro and in vivo. Mol Carcinog.
51:586–595. 2012. View
Article : Google Scholar : PubMed/NCBI
|
|
27
|
Karar J and Maity A: PI3K/AKT/mTOR pathway
in angiogenesis. Front Mol Neurosci. 4:512011. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Slomovitz BM and Coleman RL: The
PI3K/AKT/mTOR pathway as a therapeutic target in endometrial
cancer. Clin Cancer Res. 18:5856–5864. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Pandurangan AK: Potential targets for
prevention of colorectal cancer: A focus on PI3K/Akt/mTOR and Wnt
pathways. Asian Pac J Cancer Prev. 14:2201–2205. 2013. View Article : Google Scholar : PubMed/NCBI
|
